GlassScriptPhysician profile
Anil Veluvolu
NPI 1124174644
$5,656.53
in general payments reported to CMS, 2019-2025
29 companies · $667 in 2025
The $667 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $1,832 · 2021: $11.92 · 2022: $108 · 2023: $558 · 2024: $655 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.92 |
| Education | $154.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,979.25 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Astrazeneca Uk Limited | $1,188.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $349.41 | 2019-2025 | |
| Novocure INC. | $262.00 | 2019 | |
| Sirtex Medical INC | $232.65 | 2024 | Sir-Spheres Microspheres |
| Tempus Ai, INC | $194.74 | 2024-2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $182.85 | 2023 | Imbruvica, Epkinly |
| Abbvie INC. | $174.05 | 2024-2025 | |
| Daiichi Sankyo INC. | $159.25 | 2019-2025 | Enhertu |
| Pfizer INC. | $149.73 | 2019-2025 | |
| Genzyme Corporation | $107.07 | 2019-2024 | |
| Astellas Pharma US INC | $90.12 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Myriad Genetic Laboratories, INC. | $83.31 | 2023 | Precisetumor |
| Merck Sharp & Dohme LLC | $83.07 | 2019-2025 | Keytruda |
| Seagen INC. | $82.65 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $68.54 | 2019-2020 | |
| Amgen INC. | $63.42 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Glaxosmithkline, LLC. | $26.28 | 2025 | Jemperli, Zejula |
| Gilead Sciences, INC. | $24.66 | 2019-2021 | |
| Ucb, INC. | $22.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.02 | 2019 | |
| Tersera Therapeutics LLC | $19.91 | 2025 | Xermelo |
| Taiho Oncology, INC. | $19.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.02 | 2024 | Opdivo |
| Beigene USA, INC. | $15.98 | 2025 | Tevimbra |
| Genentech USA, INC. | $14.80 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Advanced Accelerator Applications | $12.71 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Veluvolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.